Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

Table 1 Characteristics of patient, n (%)

Characteristics	Patients (n = 177)
Age, median	63 (33-80)
Gender
Male	125 (70.6)
Female	52 (29.4)
ECOG
0	107 (60.5)
1	70 (39.5)
Body mass index
< 25	85 (48.0)
≥ 25	89 (50.3)
Unknown	3 (1.7)
Location
Cardia	93 (52.5)
Corpus	52 (29.4)
Antrum	32 (18.1)
Histological type
Adeno	141 (79.7)
Signet-ring cell	36 (20.3)
c-T stage
1-2	29 (16.4)
3-4	148 (83.6)
c-stage
1-2	47 (26.6)
3	130 (73.4)
c-N stage
N0	24 (13.6)
N+	153 (86.4)
Grade
1-2	87 (49.2)
3	90 (50.8)
Neoadjuvant FLOT	177 (100)
Interval between surgery and last chemotherapy, days	43.3 (10-158)
Radiological response
CR	12 (6.8)
PR	91 (51.4)
SD	71 (40.1)
PD	3 (1.7)
CEA (ng/L)
> 5 ng/L	45 (25.4)
< 5 ng/L	113 (63.8)
Missing	19 (10.7)
HER-2 status
Negative	158 (89.3)
Positive	9 (5.1)
Missing	10 (5.6)
MSI
Low	142 (80.2)
High	13 (7.3)
Missing	22 (12.4)
Surgery
Total gastrectomy	145 (81.9)
Distal	27 (15.3)
Proximal	5 (2.8)
Surgery
R0	157 (88.7)
R1	20 (11.3)
p-T stage
0-2	64 (36.2)
3-4	113 (63.8)
p-N stage
N0-1	100 (56.5)
N2-3	77 (43.5)
yp stage
0	22 (12.4)
1	29 (16.4)
2	44 (24.9)
3	82 (46.3)
Total lymph node
Positive	115 (64.3)
Negative	64 (35.7)
Lymphovascular invasion
Yes	107 (60.5)
No	70 (39.5)
Perineural invasion
Yes	87 (49.2)
No	90 (50.8)
Pathological response score
CR /near CR (1)	42 (23.7)
PR (2)	76 (42.9)
Poor/unresponsive (3)	59 (33.3)
Adjuvant
Yes	150 (84.7)
No	27 (15.3)
Chemotherapy regimen (n = 150)
FLOT, median 4 (4-8)	122 (81.3)
FOLFOX	16 (10.7)
FOLFIRI	3 (2.0)
FUFA	9 (6.0)
Post operative radiotherapy
Yes	62 (35.0)
No	115 (65.0)
Relapse
No	102 (57.6)
Yes	75 (42.4)
Dead	59 (33.3)
Alive	118 (66.7)
Hb mean g/dL (anemia)
Yes	106 (59.9)
No	71 (40.1)
NLR, median	2.06 (0.76-30.0)
Low	84 (47.5)
High	91 (51.4)
PLR, median	128.4 (43.9-572)
Low	87 (49.1)
High	88 (49.7)

ECOG: Eastern Cooperative Oncology Group; FLOT: 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy; c-T: Clinic tumor stage; c-N: Clinic lymph node stage; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; MSI: Microsatellite instability; pT: Pathological tumor stage; pN: Pathological node stage; yp stage: Post neoadjuvant therapy stage; NLR: Neutrophil-to-lymphocyte count; PLR: Platelet-to-lymphocyte count; CEA: Carcinoembryonic antigen.